Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 10 Show results per page	View Search Criteria \| Help With Results

Last Modified: 10/1/1998 First Published: 11/1/1997


1.		Phase III Multicenter, Pivotal Study of Iodine 131 Anti-B1 Antibody Radioimmunotherapy for Chemotherapy-Refractory Low Grade B-Cell Non-Hodgkin's Lymphomas or Low Grade Lymphomas That Have Transformed to Higher Grade Histologies (Summary Last Modified 10/98)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				Pharmaceutical / Industry				COULTER-RIT-11-004 NCI-V97-1245

Last Modified: 6/1/2002 First Published: 2/1/2000


2.		Phase III Study of Iodine I 131 Monoclonal Antibody Anti-B1 in Patients With Relapsed or Refractory, Low Grade or Transformed Low Grade B-Cell Non-Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				19 and over				Pharmaceutical / Industry				UNMC-259-98 COULTER-CP-98-020, NCT00004874

Last Modified: 9/22/2008 First Published: 12/1/2000


3.		Phase III Randomized Study of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) With Either Rituximab or Iodine I 131 Tositumomab (Monoclonal Antibody Anti-B1) in Patients With Newly Diagnosed Follicular Non-Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				NCI				SWOG-S0016 CALGB-50102, S0016, NCT00006721, ECOG-SWOG-S0016

Last Modified: 7/1/1999 First Published: 7/1/1998


4.		hase II Study of Combined B-Cell Purging and CD34+ Enrichment of Mobilized Peripheral Blood Progenitor Cells for Autologous Hematopoietic Transplantation in Patients with Relapsed Non-Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				14 to 70				NCI, Pharmaceutical / Industry				CWRU-CELL-1497 CP-0154-010, NCI-G98-1430

Last Modified: 12/29/2008 First Published: 4/1/1999


5.		Phase II Pilot Study of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) Followed by Iodine I 131 Monoclonal Antibody Anti-B1 in Patients with Newly Diagnosed Follicular Non-Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				NCI				SWOG-9911 NCT00003784, S9911

Last Modified: 3/19/2007 First Published: 12/1/2000


6.		Phase II Study of Iodine I 131 Monoclonal Antibody Anti-B1, Followed By High-Dose Carmustine, Etoposide, Cytarabine, and Melphalan, and Autologous Peripheral Blood Stem Cell Transplantation in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				19 to 70				Pharmaceutical / Industry				UNMC-051-00 COULTER-IND-3323, NCT00006695

Last Modified: 4/10/2007 First Published: 11/20/2003


7.		Phase II Study of Iodine I 131 Tositumomab Followed By Autologous Stem Cell Transplantation in Older Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				60 to 80				NCI				FHCRC-1366.00 NCT00073931


8.		Safety and Efficacy of Iodine-131 Anti-B1 Antibody for Intermediate Grade Non-Hodgkin's Lymphoma Following First Line CHOP

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 to 80				Pharmaceutical / Industry				CP-99-032 NCT00022932


9.		Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				Pharmaceutical / Industry				CP-99-037 NCT00022945


10.		Tositumomab And Iodine I 131-Tositumomab In Patients With Relapsed Indolent Non-Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				Pharmaceutical / Industry				393229/032 NCT00240565

Select All on One Page

| | | | | | | |

A Service of the National Cancer Institute